Economic information and modeling report
Modeling overview
12 evidence topics · 11 sources
Summary
No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.
Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec
No evidence found.
Cretostimogene grenadenorepvec in published economic models of the indication
Company statements on pricing of cretostimogene grenadenorepvec
Budget impact of nadofaragene firadenovec in a United States health plan
Cost-effectiveness of radical cystectomy and bladder-sparing treatments for BCG-unresponsive carcinoma in situ
“We developed a Markov decision analytic model to assess five treatments: RC, nadofaragene, nogapendekin, pembrolizumab, and gemcitabine/docetaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For index patient 1, who is willing to try one line of therapy or proceed directly to RC, gemcitabine/docetaxel was the most cost-effective option. For index patient 2, open to two lines of therapy or upfront RC, RC was the most cost-effective. For index patient 3, willing to try up to 2 lines of FDA-approved therapy (pembrolizumab, nadofaragene, or nogapendekin) before RC, pembrolizumab was the most cost-effective option.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Current pricing of bladder-sparing treatments poses significant financial barriers, highlighting the need for better treatment selection tools and more equitable pricing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per responder of TAR-200 versus FDA-approved comparators
ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab
“The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The base-case cost-effectiveness, with each drug compared with the hypothetical comparator with a 0% CR at 3 months, were $151,000 per QALY gained for nadofaragene firadenovec, $382,000 per QALY gained for oportuzumab monatox, and $114,000 per QALY gained for pembrolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The HBPB for nadofaragene firadenovec ranged from $158,600 to $262,000 per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of nadofaragene firadenovec and pembrolizumab versus a hypothetical alternative
“Nadofaragene firadenovec, at a placeholder price 10% higher than the price of pembrolizumab, had an incremental cost-effectiveness ratio of $263 000 and $145 000 per QALY gained in CIS and non-CIS populations, respectively. Pembrolizumab had an incremental cost-effectiveness ratio of $168 000 per QALY gained for CIS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The cost-effectiveness of nadofaragene firadenovec will depend upon its price.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of pembrolizumab versus salvage intravesical chemotherapy and radical cystectomy
Cost-effectiveness of approved bladder-sparing agents in a systematic review and Markov model
“Compared with using radical cystectomy to treat patients failing BCG therapy, at a willingness-to-pay threshold of 100 000 USD, nadofaragene firadenovec was cost effective, with an incremental cost-effectiveness ratio (ICER) of 10 014 USD per quality-adjusted life year (QALY), while nogapendekin alfa inbakicept was less cost effective than nadofaragene firadenovec (ICER of 44 602 USD per QALY). Pembrolizumab, which dominated, was both less costly and more effective than the other strategies.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of salvage treatments in a German payer setting
“Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote